Part 5 - NCCN Guidelines for Patients: Pediatric ALL; Adolescents and Young Adults; Survivorship

1 Views
administrator
administrator
07/11/23

Topics Discussed:

Patient Advocacy Updates: Resources for the Cancer Community

NCCN Guidelines for Patients: Pediatric ALL; Adolescents and Young Adults; Survivorship
Dottie Shead, MS, National Comprehensive Cancer Network

Patient Advocacy Summit Overview:
Patients with cancer often have widely divergent care experiences from screening through survivorship. Differences in care delivery and outcomes may be due, in part, to varying patient needs and preferences according to age and stage of life; inconsistent implementation of guidelines, recommendations, and policies; and unintended age bias in health care. The National Comprehensive Cancer Network’s® (NCCN®) Virtual Patient Advocacy Summit provided an opportunity for a varied group of stakeholders including patients, caregivers, providers, patient advocacy organizations, policymakers, and industry to thoughtfully discuss the importance of providing quality, effective, efficient, and accessible cancer care across the patient lifespan.

The NCCN Digital Resource Booklet includes information from 25 patient advocacy organizations on their age-specific programs and resources. This Booklet was developed in conjunction with NCCN Virtual Patient Advocacy Summit: Cancer Across the Lifespan held on December 10, 2020. To view the NCCN Digital Resource Booklet visit: https://www.nccn.org/professio....nals/meetings/oncolo

This free online program was held on December 10, 2020.

Supporters:
Supported by AbbVie, Adaptive, ADC Therapeutics, AmerisourceBergen, Apobiologix, Astellas, BeiGene, Ltd., bluebird bio, Dendreon Pharmaceuticals, Eisai Inc, EMD Serono, Exact Sciences, Exelixis, Foundation Medicine, Inc., GSK, Heron, Incyte Corporation, Janssen Oncology; Pharmaceutical Companies of Johnson & Johnson, Kite, a Gilead Company, MorphoSys US, Inc., Regeneron Pharmaceuticals, Inc., Seattle Genetics, Servier, Sun Pharma Oncology, Taiho, Verastem Oncology. Supported by AstraZeneca through its NCCN Corporate Council Membership. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. This event is sponsored by Lilly Oncology. Supported by an independent educational grant from Merck & Co., Inc. This activity was made possible by Pharmacyclics, an AbbVie Company.

________________________________________________________________
About NCCN:
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. Visit https://www.nccn.org/ for more information.

Subscribe to our channel for the latest in cancer care: https://www.youtube.com/c/NCCN....video?sub_confirmati

Connect with us!
Twitter: https://twitter.com/NCCN
LinkedIn: https://www.linkedin.com/company/nccn/
Facebook: https://www.facebook.com/NCCNorg
Instagram: https://www.instagram.com/NCCNorg/

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next